Myungmoon Pharmaceutical Enters Exclusive Negotiations with 'M2N' for Majority Shareholder Stake Sale
[Asia Economy Reporter Junho Hwang] Myungmoon Pharmaceutical held a board meeting on the 4th and announced that M2N Co., Ltd. was selected as the preferred negotiation partner regarding the sale of shares by the largest shareholder.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Exclusive] 450 Billion Won Korean Investment at Risk as Canadian PE Moves to Acquire US Ascend for $99.2 Million
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Myungmoon Pharmaceutical stated that it plans to discuss major contract terms with the selected preferred negotiation partner in the future, and if specific details are finalized or important decisions are made during the process, it will disclose them later in accordance with disclosure-related laws and regulations.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
